阿尔茨海默病药物研发管道:2022。

文章的细节

引用

复制到剪贴板

卡明斯J,李G, Nahed P, Kambar MEZN,钟K,丰J, Taghva K

阿尔茨海默病药物研发管道:2022。

预防老年痴呆症(N Y)。2022年5月4日,8 (1):e12295。doi: 10.1002 / trc2.12295。eCollection 2022。

PubMed ID

35516416 (在PubMed

]

文摘

作品简介:阿尔茨海默病(AD)代表全球健康危机。治疗需要预防、延缓发病,进展缓慢,提高认知,减少广告的行为障碍。我们回顾当前的临床试验和药物治疗广告的发展。方法:我们搜查了政府网站clinicaltrials.gov哪里所有临床试验必须注册在美国进行。我们使用人工智能(AI)和机器学习(ML)方法,以确保全面检测和鉴定试验和药物的发展。我们使用常见的阿尔茨海默病研究本体(CADRO)分类药物靶点和机制的作用药物的管道。结果:2022年1月25日(本研究索引日期)172年临床试验有143间谍广告。管道包括31个特工在47个试验阶段3,82代理94年试验第二阶段,30代理在31个试验在阶段1。疾病修饰治疗代表药物试验的总数的83.2%;认知增强治疗症状代表9.8%的药物试验; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirty-seven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion: The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD. Highlights: There are 143 drugs in the current Alzheimer's disease (AD) drug development pipeline.Disease-modifying therapies represent 83.2% of the candidate treatments.Current trials require 50,575 participants who will donate 3,878,843 participant-weeks to clinical trials.The biopharmaceutical industry sponsors 50% of all clinical trials including 68% of Phase 3 trials.Sixty-three percent of Phase 3 trials and 46% of Phase 2 trials include non-North American clinical trial site locations indicating the global ecosystem required for AD drug development.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Lecanemab